Sibylla Biotech

Sibylla Biotech is a preclinical stage company that develops small molecule degraders using a platform powered by computer simulations and AI. The company utilizes a proprietary technology called Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) to discover compounds that interfere with protein folding pathways. This approach is applied to identify and develop therapeutics for unmet medical needs across various therapeutic areas, including central nervous system disorders and oncology.